frequent occurrence of hematoma at the injection site. The dosage of heparin sodium should be adjusted according to the patient’s coagulation test results.
When heparin is given by continuous intravenous infusion, the coagulation time should be determined
approximately every 4 hours in the early stages of treatment. When the drug is administered
intermittently by intravenous injection, coagulation tests should be performed before each injection
during the early stages of treatment and at appropriate intervals thereafter. Dosage is considered
adequate when the activated partial thromboplastin time (APTT) is 1.5 to 2 times normal or when the
whole blood clotting time is elevated approximately 2.5 to 3 times the control value. After deep
subcutaneous (intrafat) injections, tests for adequacy of dosage are best performed on samples drawn 4
to 6 hours after the injection.
Periodic platelet counts, hematocrits and tests for occult blood in stool are recommended during the
entire course of heparin therapy, regardless of the route of administration.
Converting to Oral Anticoagulant When an oral anticoagulant of the coumarin or similar type is to be begun in patients already receiving
heparin sodium, baseline and subsequent tests of prothrombin activity must be determined at a time
when heparin activity is too low to affect the prothrombin time. This is about 5 hours after the last
intravenous bolus and 24 hours after the last subcutaneous dose. If continuous IV heparin infusion is
used, prothrombin time can usually be measured at any time.
In converting from heparin to an oral anticoagulant, the dose of the oral anticoagulant should be the
usual initial amount and thereafter prothrombin time should be determined at the usual intervals. To
ensure continuous anticoagulation, it is advisable to continue full heparin therapy for several days after
the prothrombin time has reached the therapeutic range. Heparin therapy may then be discontinued
without tapering.